Starting or switching to bictegravir/emtricitabine/tenofovir alafenamide in clinical practice: pooled 12-month results from the global BICSTaR study

被引：0
|
作者：
Spinner, C. [1 ]
Stoehr, A. [2 ]
Wong, A. [3 ]
de Wet, J. [4 ]
Zeggagh, J. [5 ]
Hocqueloux, L. [6 ]
van Welzen, B. [7 ]
Heinzkill, M. [8 ]
Sahali, S. [9 ]
Cornejo, A. Torres [10 ]
Ramroth, H. [11 ]
Haubrich, R. [12 ]
Thorpe, D. [13 ]
Kim, C. [14 ]
机构：
[1] Tech Univ Munich, Univ Hosp Rechts Isar, Sch Med, Munich, Germany
[2] IFI Studien & Projekte GmbH, Zentrum Infektiol, Hamburg, Germany
[3] Univ Saskatchewan, Dept Med, Regina, SK, Canada
[4] Spectrum Hlth, Vancouver, BC, Canada
[5] Hop St Louis, AP HP, Serv Malad Infect, Paris, France
[6] CHR Orleans, Serv Malad Infect & Trop, Orleans, France
[7] Univ Med Ctr, Internal Med & Infect Dis, Utrecht, Netherlands
[8] Gilead Sci GmbH, HIV Med Affairs, Munich, Germany
[9] Gilead Sci, HIV Med Affairs, Paris, France
[10] Gilead Sci Netherlands BV, HIV Med Affairs, Amsterdam, Netherlands
[11] Gilead Sci Ltd, Pharmacovigilance & Epidemiol, London, England
[12] Gilead Sci Inc, Med Affairs Res, 353 Lakeside Dr, Foster City, CA 94404 USA
[13] Gilead Sci Europe Ltd, HIV Med Affairs, London, England
[14] Gilead Sci Canada Inc, HIV Med Affairs, Mississauga, ON, Canada
来源：
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
P046
引用
收藏
页码：50 / 51
页数：2
相关论文
共 50 条
  • [21] Switching to Dolutegravir/lamivudine or Bictegravir/Emtricitabine/Tenofovir alafenamide. A comparative real-world study
    Knobel, Hernando
    Canas-Ruano, Esperanza
    Guelar, Ana
    Knobel, Pablo
    Villar-Garcia, Judit
    Gonzalez-Mena, Alicia
    Canepa, Ceclia
    Arrieta-Aldea, Itziar
    Marcos, Augustin
    Abalat-Torrres, Agusti
    Gerri-Fernandez, Roberto
    HIV RESEARCH & CLINICAL PRACTICE, 2023, 24 (01)
  • [22] Associations with HIV-related symptoms and weight change after switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate to bictegravir/emtricitabine/tenofovir alafenamide
    Lowman, E.
    Hardigan, P.
    Unger, N.
    Lee, N.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 75 - 75
  • [23] Effectiveness, safety and tolerability of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in HIV-1 infected adult patients in routine clinical practice-6 months results of the BICSTaR cohort
    Esser, S.
    Jessen, H.
    Schneider, J.
    Schellberg, S.
    Stellbrink, H-J
    Waizmann, M.
    Hillenbrand, H.
    Bilbao, P.
    Schreiber, S.
    Thorpe, D.
    Ramroth, H.
    Haubrich, R.
    Heinzkill, M.
    HIV MEDICINE, 2019, 20 : 61 - 61
  • [24] Comparing the efficacy and safety of a first-line regimen with emtricitabine/tenofovir alafenamide fumarate plus either bictegravir or dolutegravir: Results from clinical practice
    Ciccullo, Arturo
    Baldin, Gianmaria
    Borghi, Vanni
    Oreni, Letizia
    Lagi, Filippo
    Fusco, Paolo
    Giacomelli, Andrea
    Torti, Carlo
    Sterrantino, Gaetana
    Mussini, Cristina
    Antinori, Spinello
    Di Giambenedetto, Simona
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2024, 63 (01)
  • [25] Comparing lamivudine plus dolutegravir and bictegravir/emtricitabine/ tenofovir alafenamide in antiretroviral therapynaive HIV-infected patients: preliminary results from clinical practice
    Long, H.
    HIV MEDICINE, 2023, 24 : 105 - 106
  • [26] Outcomes after switching from 144 weeks of blinded dolutegravir/abacavir/lamivudine or dolutegravir plus emtricitabine/tenofovir alafenamide to 96 weeks of open-label bictegravir/emtricitabine/tenofovir alafenamide
    Orkin, Chloe
    Antinori, Andrea
    Rockstroh, Juergen
    Guillen, Santiago Moreno
    Martorell, Claudia
    Molina, Jean-Michel
    Lazzarin, Adriano
    Maggiolo, Franco
    Yazdanpanah, Yazdan
    Andreatta, Kristen
    Huang, Hailin
    Hindman, Jason
    Martin, Hal
    Baeten, Jared
    Pozniak, Anton
    HIV MEDICINE, 2023, 24 : 21 - 22
  • [27] Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) for the treatment of people living with HIV (PLWH): 12-month (12M) effectiveness, persistence and safety in a multi-country cohort study
    Mallolas, Josep
    Esposito, Vincenzo
    Hocqueloux, Laurent
    Lambert, John S.
    Levy, Itzchak
    Wyen, Christoph
    van Welzen, Berend
    Ustianowski, Andrew
    Schreiber, Sandra
    Thorpe, David
    Heinzkill, Marion
    Marongiu, Andrea
    Haubrich, Richard
    Loemba, Hugues
    HIV MEDICINE, 2022, 23 : 29 - 29
  • [28] Patient-reported outcomes (PROs) after 1 year of routine clinical practice with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in people living with HIV (PLWH): the BICSTaR cohort
    Knechten, H.
    Milinkovic, A.
    Stephan, C. C.
    Brunetta, J.
    Trottier, B.
    Bonnet, F.
    Duvivier, C.
    Welzen, B. V.
    Mack, F.
    Tossonian, H.
    Thorpe, D.
    Cornejo, A. T.
    Marongiu, A.
    Curbelo, R.
    HIV MEDICINE, 2021, 22 : 31 - 32
  • [29] Switching to a single-tablet regimen bictegravir, emtricitabine, and tenofovir alafenamide (B/F/TAF) from dolutegravir (DTG) plus emtricitabine and either tenofovir alafenamide or tenofovir disoproxil fumarate (F/TAF or F/TDF)
    Sax, P. E.
    Rockstroh, J.
    Luetkemeyer, A.
    Yasdanpanah, Y.
    Ward, D.
    Trottier, B.
    Rieger, A.
    Liu, H.
    Acosta, R.
    Collins, S. E.
    Brainard, D.
    Martin, H.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2019, 22 : 3 - 4
  • [30] Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) for the treatment of people living with HIV (PLWH): 12-month (12M) effectiveness, persistence, and safety in a multi-country cohort study
    Mallolas, J.
    Esposito, V.
    Hocqueloux, L.
    Lambert, J. S.
    Levy, I.
    Wyen, C.
    van Welzen, B.
    Ustianowski, A.
    Schreiber, S.
    Thorpe, D.
    Heinzkill, M.
    Marongiu, A.
    Haubrich, R.
    Loemba, H.
    HIV MEDICINE, 2021, 22 : 115 - 116
12345